More than half a century ago, Robert Wilson [1] recognized that charged particles held an intrinsic potential advantage for cancer therapy, compared with gamma rays and x-rays, and that accelerators capable of accelerating protons or heavier ions to sufficiently high energy would soon be readily available. Since the specific ionization (energy loss per unit distance) of non-relativistic ions varies nearly inversely with the kinetic energy, the radiological dose is greatest near the end of the ion path, in the 'Bragg Peak', named in honor of William Henry Bragg, who discovered the effect in 1903 [2]. Wilson proposed that with sufficient knowledge of the specific ioniz ation, or 'proton stopping power', of the tissue between skin and tumor, the ion energy could be tuned such that the ions stop in the tumor, resulting in minimal dose proximal to the tumor and nearly zero dose distal to the tumor. See figure 1 for a comparison of charged-particle irradiation with x-ray or gamma irradiation, for which the depth of the ionizing interactions cannot be controlled. In the figure, the broad flat proton dose distribution in the tumor region is realized